Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33335 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL11100623 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL9023160 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL5571338 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL22186740 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL5574655 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL307959 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL5273324 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL20610044 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL9835189 | 1.00 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171214-A1 | BIORESORBABLE SURFACE COATING FOR DELAYING DEGRADATION | DREI LILIEN PVG GMBH & CO. KG (DE) | 2020-06-04 | — | — | US | disclosed |
| CN-107162981-B | Antibacterial polymerizable monomer containing halogenated imidazole salt structure and preparation method and application thereof | 华南理工大学 | 2020-05-22 | — | — | CN | disclosed |
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | MARTEK BIOSCIENCES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2007019478-A2 | DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190399-A1 | Synthesis and use of omega-3 and omega 6 very long chain polyunsaturated fatty acids (VLC-PUFA) | ELOVL3, ELOVL6, ELOVL1 | TSHR 3389/4885THRB 3039/4885DNM1 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.